Adverse Event Reporting Deluge Diagnosed By IRB Reps At FDA Hearing
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial sponsors should assume oversight of safety data that currently burden institutional review boards, participants agreed at an FDA public hearing on adverse event (AE) reporting to IRBs